Search

Displaying results 1371 - 1380 of 10000 in total
  1. Drug

    Midazolam

    go.drugbank.com/drugs/DB00683
    ApprovedIllicitInvestigational

    [L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. … [A257153] Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence.[L5074]

    Products: SEDEVER 15MG/3ML REKTAL UYGULAMA VE IV/IM ENJEKSIYON VE INFÜZYON IÇIN ÇÖZELTI, SEDEVER 50MG/10ML REKTAL UYGULAMA VE IV/IM ENJEKSIYON VE INFÜZYON IÇIN ÇÖZELTI
  2. Target

    Transient receptor potential cation channel subfamily V member 1

    go.drugbank.com/bio_entities/BE0001023
    TargetHumans

    Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. … Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL.

    Polypeptides: Transient receptor potential cation channel subfamily V member 1Synonyms: Capsaicin receptor, Vanilloid receptor 1
  3. Target

    Low affinity immunoglobulin gamma Fc region receptor II-a

    go.drugbank.com/bio_entities/BE0002098
    TargetHumans

    Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: IgG Fc receptor II-a
  4. Target

    Transient receptor potential cation channel subfamily V member 2

    go.drugbank.com/bio_entities/BE0009158
    TargetHumans

    Calcium-permeable, non-selective cation channel (PubMed:10201375). Seems to be regulated, at least in part, by growth factors, such as IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells...

    Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1
  5. Target

    Ankyrin repeat and protein kinase domain-containing protein 1

    go.drugbank.com/bio_entities/BE0009411
    TargetHumans

    Polypeptides: Ankyrin repeat and protein kinase domain-containing protein 1
  6. Target

    Transient receptor potential cation channel subfamily M member 3

    go.drugbank.com/bio_entities/BE0009808
    TransporterHumans

    Suggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion.

    Polypeptides: Transient receptor potential cation channel subfamily M member 3Synonyms: Long transient receptor potential channel 3
  7. Drug

    Carfentanil

    go.drugbank.com/drugs/DB01535
    IllicitInvestigationalVet approved

    Carfentanil or carfentanyl (Wildnil) is an analogue of the popular synthetic opioid analgesic fentanyl, and is one of the most potent opioids known (also the most potent opioid used commercially). … Currently sufentanil, approximately 10–20 times less potent (500 to 1000 times the efficacy of morphine per weight) than carfentanil, is the maximum strength fentanyl analog for use in humans.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Thiocolchicoside

    go.drugbank.com/drugs/DB11582
    Investigational

    It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663] … Thiocolchicoside is a semi-synthetic derivative of the colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of _Superba gloriosa_.

    Products: MUSCORIL CONTRATTURE E DOLORE, MIOTENS CONTRATTURE E DOLORE
  9. Drug

    Branaplam

    go.drugbank.com/drugs/DB14918
    Investigational

    Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

  10. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … And finally, although brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet

    Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Neuroactive Steroid Gamma-Aminobutyric Acid (GABA) A Receptor Positive Modulators